Sudden Departure Of A Veteran Healthcare Dealmaker
Bausch + Lomb disclosed on Monday that CEO Brent Saunders has stepped down from his executive duties by mutual consensus with the board, concluding his second leadership tenure at the historic eye-care manufacturer. The enterprise did not disclose a rationale for his departure, leaving market participants speculating on strategic disagreements regarding corporate independence.
Chairman Thomas Appio assumed interim chief executive responsibilities immediately. Appio has served as CEO of majority-owner Bausch Health since 2022 and previously directed Bausch + Lomb’s global international commercial operations, providing operational familiarity during the leadership void.
"The timing of Saunders’ departure seems sudden, but Appio’s long experience at Bausch + Lomb positions him well to lead the company during the transition." — Citi Equity Research Analyst Note
Earnings Guidance Upgrades Counterbalance Market Volatility
While public market trading responded with an immediate 5% decline in Bausch + Lomb equity valuation, forward-looking operational metrics painted a resilient commercial picture.

















